Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to,
on the day of and on days after treatment with eribulin. Different doses and dosing
frequencies will be investigated